<?xml version="1.0" encoding="UTF-8"?>
<p>Current guidelines recommend that remdesivir (five-day course) be prioritized for hospitalized SARS-CoV-2 patients who are on supplemental oxygen but do not require high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) [
 <xref rid="REF24" ref-type="bibr">24</xref>]. Remdesivir is a broad-spectrum antiviral medication that works by targeting viral RNA polymerase and terminating viral transcription. This medication was first trialed back in January on a SARS-CoV-2 patient, who later was noted to recover rather remarkably [
 <xref rid="REF7" ref-type="bibr">7</xref>]. Early studies showed high in vitro potency effects, favorable side effect profiles, and improvements in oxygen support among patients receiving compassionate remdesivir [
 <xref rid="REF38" ref-type="bibr">38</xref>-
 <xref rid="REF39" ref-type="bibr">39</xref>]. However, several large clinical trials were launched by both Gilead (SIMPLE trials) and the NIH (ACTT trial) to evaluate the true efficacy of this medication [
 <xref rid="REF40" ref-type="bibr">40</xref>-
 <xref rid="REF42" ref-type="bibr">42</xref>].
</p>
